Introduction
Intravesical bacillus Calmette-Guérin (BCG) therapy is the
gold standard adjuvant treatment for patients with high-grade
non-muscle-invasive bladder cancer (NMIBC). Despite the association between
metabolic syndrome (MetS) and bladder cancer, the association between MetS
and BCG failure is unknown. The objective of this study was to characterize
disease recurrence following BCG in patients with and without MetS.
Methods
We retrospectively evaluated the records of patients undergoing TURBT
at our institution in 2012–2015 for NMIBC and identified those who
received adjuvant BCG therapy. MetS was defined as having three of four
components: diabetes mellitus, hyperlipidemia, hypertension, or body mass
index (BMI)≥30kg/m2. The primary outcome was recurrence
or progression. Descriptive statistics, chi-squared analysis, Kaplan-Meier
survival analysis, and Cox multivariable regression analyses were
performed.
Results
High grade was present in 83/90 (92.2%) patients. MetS was
present in 27/90 (30%) patients. Median follow-up was 20 months. On
Kaplan-Meier analysis, patients with MetS had worse DFS compared with
patient without MetS. On multivariable analysis, BMI≥30
kg/m2 was a significant predictor of recurrence or
progression (HR 2.94, 95% CI: 1.43–6.03). Presence of MetS
did not significantly affect the type of BCG failure.
Conclusions
The association between MetS and failure to respond to BCG therapy is
multifactorial but is in part associated with obesity. Elevated BMI is
strongly associated with recurrence or progression. Further studies are
warranted to investigate the relationship between increased adiposity and
response to BCG, especially as other novel immunotherapeutic agents are
likely to enter the NMIBC space.
BackgroundIntravesical Mitomycin-C (MMC) following transurethral resection of bladder tumor (TURBT), while efficacious, is associated with side effects and poor utilization. Continuous saline bladder irrigation (CSBI) has been examined as an alternative. In this study we sought to compare the rates of recurrence and/or progression in patients with NMIBC who were treated with either MMC or CSBI after TURBT.MethodsWe retrospectively reviewed records of patients with NMIBC at our institution in 2012–2015. Perioperative use of MMC (40 mg in 20 mL), CSBI (two hours), or neither were recorded. Primary outcome was time to recurrence or progression. Descriptive statistics, chi-squared analysis, Kaplan-Meier survival analysis, and Cox multivariable regression analyses were performed.Results205 patients met inclusion criteria. Forty-five (22.0%) patients received CSBI, 71 (34.6%) received MMC, and 89 (43.4%) received no perioperative therapy. On survival analysis, MMC was associated with improved DFS compared with CSBI (p = 0.001) and no treatment (p = 0.0009). On multivariable analysis, high risk disease was associated with increased risk of recurrence or progression (HR 2.77, 95% CI: 1.28–6.01), whereas adjuvant therapy (HR 0.35, 95% CI: 0.20–0.59) and MMC (HR 0.43, 95% CI: 0.25–0.75) were associated with decreased risk.ConclusionsPostoperative MMC was associated with improved DFS compared with CSBI and no treatment. The DFS benefit seen with CSBI in other studies may be limited to patients receiving prolonged irrigation. New intravesical agents being evaluated may consider saline as a control given our data demonstrating that short-term CSBI is not superior to TURBT alone.
We present a case of an 18-year-old female with neurofibromatosis type 1 who presented with abdominal pain and weight loss secondary to chronic mesenteric ischemia due to celiac axis occlusion and was subsequently found to have multiple visceral artery aneurysms. Of clinical significance, 2 aneurysms of the right renal artery were noted at the hilum, with the larger one having a diameter of 2.4 cm. After initial endovascular treatment with stenting of a concurrent pancreaticoduodenal artery pseudoaneurysm, staged aorto-hepatic bypass and right nephrectomy with renal autotransplantation after back table resection of the aneurysmal segments were successfully completed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.